If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): Next Injection After Post Injection Syndrome
The majority of patients in clinical trials who experienced a post-injection syndrome event continued olanzapine. A general recommendation for the next injection is not available.
patients fully recovered from the post-injection syndrome event
within 1.5 to 72 hours after onset.1
70% of events, patients continued to receive further treatment with
olanzapine LAI following the event. At the time of datalock, the
median number of additional days of study participation following a
post-injection syndrome event was 184 days, and the median number of
subsequent injections received following the event was 9. Only 1
patient experienced a second post-injection syndrome event, with the
second event occurring approximately 6 months after the first
an analysis of 338 postmarketing cases from 01 March 2009 through
01 March 2014, among the 210 cases where continuation
information was available, 55% (116/210) of patients continued
olanzapine LAI treatment.2
olanzapine LAI therapy is continued, the dose and timing of the next
injection may occur as previously scheduled or earlier if clinically
indicated for exacerbation of schizophrenia symptoms.3
oral olanzapine supplementation may be considered if clinically
indicated. Then the combined total dose of olanzapine from both
formulations should not exceed the corresponding maximum oral
olanzapine dose of 20 mg/day.4
olanzapine pamoate therapy is discontinued, treatment efficacy and/or
treatment-emergent AEs may continue for some time.4
half-life of olanzapine after olanzapine pamoate is 30 days compared
to 30 hours following oral administration.4
Detke HC, McDonnell DP, Brunner E, et al. Post-injection
delirium/sedation syndrome in patients with schizophrenia treated
with olanzapine long acting injection, I: analysis of cases. BMC
Bushe CJ, Falk D, Anand E, et al. Olanzapine long-acting injection:
a review of first experiences of post-injection delirium/sedation
syndrome in routine clinical practice. BMC Psychiatry.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
=Long Acting Injection
Date of Last Review:December 12, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com